Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009

Bipolar Disorders - Tập 11 Số 3 - Trang 225-255 - 2009
Lakshmi N. Yatham1, Sidney H. Kennedy1, Ayal Schaffer1, Sagar V. Parikh1, Serge Beaulieu1, Claire O’Donovan1, Glenda MacQueen1, Roger S. McIntyre1, Verinder Sharma1, Arun Ravindran1, L. Trevor Young1, Allan H. Young1, Martin Alda1, Roumen Milev1, Eduard Vieta1, Joseph R. Calabrese1, Michael Berk1, Kyooseob Ha1, Flávio Kapczinski1
1AffiliationsaDepartment of Psychiatry, University of British Columbia, Vancouver, BC, bDepartment of Psychiatry, University of Toronto, Toronto, ON, cDepartment of Psychiatry, McGill University, Montreal, QC, dDepartment of Psychiatry, Dalhousie University, Halifax, NS, eDepartment of Psychiatry, University of Calgary, Calgary, Alberta, fDepartment of Psychiatry, University of Western Ontario, London, ON, gDepartment of Psychiatry, Queen's University, Kingston, ON, Canada, hBipolar Disorder Program, University of Barcelona Hospital Clinic, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain, iMood Disorders Program, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA, jDepartment of Clinical and Biomedical Sciences, University of Melbourne, Parkville, Australia, kDepartment of Psychiatry, Seoul National University, Seoul, Korea, lBipolar Disorders Program, Department of Psychiatry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

Tóm tắt

The Canadian Network for Mood and Anxiety Treatments (CANMAT) published guidelines for the management of bipolar disorder in 2005, with a 2007 update. This second update, in conjunction with the International Society for Bipolar Disorders (ISBD), reviews new evidence and is designed to be used in conjunction with the previous publications.The recommendations for the management of acute mania remain mostly unchanged. Lithium, valproate, and several atypical antipsychotics continue to be first‐line treatments for acute mania. Tamoxifen is now suggested as a third‐line augmentation option. The combination of olanzapine and carbamazepine is not recommended. For the management of bipolar depression, lithium, lamotrigine, and quetiapine monotherapy, olanzapine plus selective serotonin reuptake inhibitor (SSRI), and lithium or divalproex plus SSRI/bupropion remain first‐line options. New data support the use of adjunctive modafinil as a second‐line option, but also indicate that aripiprazole should not be used as monotherapy for bipolar depression. Lithium, lamotrigine, valproate, and olanzapine continue to be first‐line options for maintenance treatment of bipolar disorder. New data support the use of quetiapine monotherapy and adjunctive therapy for the prevention of manic and depressive events, aripiprazole monotherapy for the prevention of manic events, and risperidone long‐acting injection monotherapy and adjunctive therapy, and adjunctive ziprasidone for the prevention of mood events.Bipolar II disorder is frequently overlooked in treatment guidelines, but has an important clinical impact on patients’ lives. This update provides an expanded look at bipolar II disorder.

Từ khóa


Tài liệu tham khảo

10.1111/j.1399-5618.2005.00219.x

10.1111/j.1399-5618.2006.00432.x

10.1001/archpsyc.64.5.543

10.1111/j.1399-5618.2007.00556.x

10.1016/j.jad.2008.02.009

10.1016/j.jad.2007.08.003

Lopez J, 2008, Diagnostic errors and temporal stability in bipolar disorder, Actas Esp Psiquiatr, 36, 205

10.1016/j.pnpbp.2006.08.003

10.1016/j.jad.2007.09.006

10.1348/147608308X278105

10.1097/JCP.0b13e318033bd5e

10.1002/hup.870

10.1111/j.1399-5618.2007.00468.x

10.1001/archpsyc.64.4.442

10.1016/j.jad.2007.04.020

10.1002/14651858.CD004043.pub2

10.4088/JCP.v67n1112

10.4088/JCP.v66n0116

10.1016/j.euroneuro.2005.02.006

10.1097/00004583-200210000-00011

10.1111/j.1399-5618.2004.00115.x

10.1097/01.jcp.0000144887.66319.2f

10.1016/j.jad.2007.02.006

10.1016/j.jad.2007.02.008

10.2146/ajhp060527

10.1016/j.jad.2007.02.004

10.1016/j.jad.2007.02.009

10.1016/j.jad.2007.02.007

CutlerA DattoC NordenhemAet al.Effectiveness of extended‐release formulation of quetiapine as monotherapy for the treatment of acute bipolar mania (trial D144CC00004) [abstract NR3‐006]. Annual meeting of the American Psychiatric Association. Washington D.C. 2008.

10.1177/0269881106059693

10.1176/appi.ajp.160.9.1651

10.1192/bjp.187.3.235

10.1016/j.jad.2007.08.015

10.4088/JCP.v68n0908

10.1176/appi.ajp.2008.07101560

Vieta E, 2008, New Research Abstracts, Annual Meeting of the American Psychiatric Association

10.1111/j.1600-0447.2006.00912.x

10.1016/S0924-977X(08)70525-X

CutlerAA randomized double‐blind placebo‐controlled parallel‐group dose‐response multicenter study to evaluate the efficacy and safety of three fixed doses of extended‐release paliperidone (3 6 and 12 mg/day) in the treatment of subjects with acute manic and mixed episodes associated with bipolar I disorder. Veritas Medicine. January 7 2008. Available at:http://www.download.veritasmedicine.com/PDF/CR010834_CSR.pdf. Accessed February 11 2009.

Hirschfeld R, 2007, New Research Abstracts, Annual Meeting of the American Psychiatric Association

Panagides J, 2007, Asenapine in acute mania: a randomized, double‐blind, placebo‐ and olanzapine‐controlled trial (ARES 7501004), Biol Psychiatry, 61, 222S

McIntyre R, 2008, Asenapine in the treatment of acute mania in bipolar I disorder: outcomes from two randomized placebo‐controlled trials, Bipolar Disord, 10, 49

Calabrese J, 2008, New Research Abstracts, Annual Meeting of the American Psychiatric Association

10.1002/14651858.CD004362.pub2

10.1001/archgenpsychiatry.2007.43

10.1111/j.1399-5618.2007.00530.x

10.1016/j.psyneuen.2005.11.001

Kulkarni J, 2008, Tamoxifen – a potential treatment for women in the manic phase of bipolar affective disorder?, Bipolar Disord, 10, 80

10.1176/ajp.2006.163.7.1179

10.1111/j.1399-5618.2007.00466.x

10.1111/j.1399-5618.2006.00363.x

Thomas P, 2008, Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open‐label, randomized, comparative trial, Neuropsychiatr Dis Treat, 4, 1

10.1192/bjp.bp.107.041301

RiesenbergR.A randomized double‐blind placebo‐controlled parallel‐group multicenter study to evaluate the efficacy and safety of flexibly‐dosed extended‐release paliperidone as adjunctive therapy to mood stabilizers in the treatment of acute manic and mixed episodes associated with bipolar I disorder. Veritas Medicine. Feb 25 2008. Available at:http://www.download.veritasmedicine.com/PDF/CR010855_CSR.pdf. Accessed February 11 2009.

10.1097/JCP.0b013e318033bd4a

10.1001/archpsyc.64.4.419

10.1176/appi.ajp.2007.07020311

10.4088/JCP.v60n0203

10.1097/00004714-200012000-00004

10.1111/j.1399-5618.2007.00500.x

10.1192/bjp.bp.107.048504

10.1176/appi.ajp.162.7.1351

10.1097/01.jcp.0000248603.76231.b7

Young A, 2008, New Research Abstracts, Annual Meeting of the American Psychiatric Association

Olausson B, 2008, New Research Abstracts, Annual Meeting of the American Psychiatric Association

Suppes T, 2008, New Research Abstracts, Annual Meeting of the American Psychiatric Association

10.1056/NEJMoa064135

10.1176/appi.ajp.2007.05122032

10.1176/appi.ajp.2007.06060981

10.1016/j.jad.2006.01.010

10.2165/00003495-200868130-00003

10.1016/j.jad.2004.09.009

10.4088/JCP.v68n1203

Muzina D, 2008, New Research Abstracts, Annual Meeting of the American Psychiatric Association

10.1111/j.1600-0447.2007.00993.x

10.1016/j.biopsych.2008.04.022

10.1097/jcp.0b013e3181618eb4

10.1080/10401230600801176

10.1345/aph.1H294

10.1016/j.jad.2008.01.004

10.1016/j.pnpbp.2006.12.009

10.1080/15622970601136203

10.1016/j.jad.2006.11.025

10.1097/MLR.0b013e318040ad90

10.1176/appi.ajp.163.2.217

10.1176/appi.ajp.2007.05081484

10.1001/archpsyc.65.4.386

10.1016/j.jad.2007.08.014

10.1002/14651858.CD004854.pub2

10.1192/bjp.bp.107.037887

10.3310/hta11390

Justo LP, 2007, Family interventions for bipolar disorder, Cochrane Database Syst Rev

10.1111/j.1399-5618.2008.00588.x

10.4088/JCP.v67n0215

10.1016/j.jad.2007.08.022

Parikh S, 2007, New Research Abstracts, Annual Meeting of the American Psychiatric Association

10.1177/070674370805300709

10.1111/j.1399-5618.2007.00490.x

YoungA McElroyS OlaussonBet al.Quetiapine Monotherapy up to 52 weeks in patients with bipolar depression: continuation phase data from EMBOLDEN I & II [Abstract]. Barcelona Spain:21st ENCP Conference 2008.

Nolen W, 2008, New Clinical Data in the Maintenance Treatment of Bipolar Disorder

Vieta E, 2008, Efficacy and safety of quetiapine in combination with lithium/divalproex as maintenance treatment for bipolar I disorder, Bipolar Disord, 10, 57

Suppes T, 2008, Maintenance treatment in bipolar I disorder with quetiapine concomitant with lithium or divalproex: a placebo‐controlled, randomized multicenter trial (Trial D1447C00127), Bipolar Disord, 10, 40

Brecher M, 2008, New Research Abstracts, Annual Meeting of the American Psychiatric Association

10.1111/j.1399-5618.2007.00389.x

10.1016/j.pnpbp.2006.08.007

10.4088/JCP.v68n1012

Yatham LN, 2008, Current Maintenance Treatments for Bipolar Disorder

10.1016/S0924-977X(08)70650-3

10.4088/JCP.v67n0414

10.4088/JCP.v68n1003

Forbes A, 2008, New Research Abstracts, Annual Meeting of the American Psychiatric Association

Vieta E, 2009, 17th European Congress of Psychiatry

10.1017/S1461145708008596

10.1016/j.jad.2006.08.013

10.1056/NEJMoa066584

10.1056/NEJMoa067407

10.1001/archpedi.160.2.173

10.1056/NEJMoa052744

10.1192/bjp.bp.107.041541

10.1176/appi.ajp.2007.06111886

10.1176/appi.ajp.2007.06101639

10.1111/j.1399-5618.2007.00565.x

10.1111/j.0013-9580.2004.451105.x

Food and Drug Administration.Information for Healthcare Professionals. Lamotrigine (marketed as Lamictal). Jan 31 2008. Available at:http://www.fda.gov/CDER/drug/InfoSheets/HCP/lamotrigineHCP.htm. Accessed January 24 2009.

10.4088/JCP.v68n1217

10.1111/j.1399-5618.2008.00606.x

10.1111/j.1471-0528.2007.01563.x

10.1192/bjp.164.4.517

10.1192/bjp.171.6.550

Farías M, 2007, Adaptación de la Escala Highs para la detección de sintomatología hipomaníaca en el puerperio, Trastor Ánimo, 3, 27

10.1111/j.1399-5618.2005.00185.x

10.1111/j.1399-5618.2006.00336.x

10.2165/00023210-200620030-00002

10.1097/JCP.0b013e31815a5819

10.1097/01.jcp.0000236656.70544.f3

10.1097/AOG.0b013e31816fd910

10.1097/01.chi.0000242240.69678.c4

10.1176/ajp.2007.164.4.582

10.1177/070674370705200507

10.1089/cap.2007.0057

10.1111/j.1399-5618.2008.00480.x

10.1097/01.chi.0000246068.85577.d7

10.1017/S0954579406060627

10.1176/appi.ajp.2007.06111932

10.1097/01.chi.0000194567.63289.97

10.1089/cap.2006.16.665

DelBello M, 2008, New Research Abstracts, Annual Meeting of the American Psychiatric Association

10.1111/j.1399-5618.2007.00450.x

Forbes A, 2008, New Research Abstracts, Annual Meeting of the American Psychiatric Association

10.1017/S1092852900021519

Tramontina S, 2007, Aripiprazole in juvenile bipolar disorder comorbid with attention‐deficit/hyperactivity disorder: an open clinical trial, CNS Spectr, 12, 758, 10.1017/S1092852900015443

10.1016/j.euroneuro.2006.11.006

10.1097/chi.0b013e31814b8d3b

10.1111/j.1399-5618.2007.00393.x

10.1016/j.jad.2007.05.014

10.1111/j.1399-5618.2007.00498.x

10.1097/JGP.0b013e31802dd367

10.1002/gps.1751

10.1017/S1041610208007084

10.1097/JCP.0b013e318166dfed

10.1097/JGP.0b013e318157c5b1

10.1002/gps.1527

10.1176/appi.ajp.163.2.319

10.4088/JCP.v69n0106

10.1097/01.jcp.0000264996.08901.3c

10.1097/01.JGP.0000224657.37446.9b

10.1002/gps.1962

10.1002/gps.2016

10.1002/gps.1460

10.1002/da.20273

10.1111/j.1399-5618.2007.00397.x

10.1001/archgenpsychiatry.2007.18

10.1111/j.1399-5618.2007.00346.x

10.4088/JCP.v68n0802

10.1016/j.jad.2008.01.018

10.1176/ps.2006.57.8.1140

10.1016/j.jad.2007.09.003

10.4088/JCP.v67n0807

10.1007/s00127-007-0222-z

10.1176/appi.psy.49.2.109

10.4088/JCP.v69n0413

Sheehan DV, 2008, Randomized, placebo‐controlled trial of risperidone for acute treatment of bipolar anxiety, J Affect Disord

10.2165/00023210-200721090-00003

10.1111/j.1399-5618.2007.00467.x

10.1016/j.jad.2007.06.014

10.1016/j.jad.2007.01.035

10.4088/JCP.v68n0205

10.1111/j.1399-5618.2007.00492.x

10.1192/bjp.bp.105.017269

10.1111/j.1399-5618.2007.00561.x

10.1001/archpsyc.58.11.1025

10.1177/070674370404901202

10.4088/JCP.v68n0114

10.1176/ps.2007.58.1.85

10.1080/15622970701317265

10.1111/j.1399-5618.2007.00479.x

10.4088/JCP.v67n0304

Liebowitz M, 2008, New Research Abstracts, Annual Meeting of the American Psychiatric Association

10.1016/j.jad.2008.02.004

Ketter TA, 2007, Divalproex‐extended release monotherapy and adjunctive therapy in bipolar II depression, Bipolar Disord, 9, 58

10.1016/j.jad.2006.01.024

10.1097/YIC.0b013e3280c28410

10.1097/JCP.0b013e318166c4e6

Aaronson S, 2008, New Research Abstracts, Annual Meeting of the American Psychiatric Association

10.1176/appi.ajp.163.2.313

10.4088/JCP.v69n1009

10.1016/j.jad.2008.01.029

Jung I, 2008, Lamotrigine treatment for patients with bipolar II disorder: retrospective report of 30 cases, Bipolar Disord, 10, 45

10.1016/j.jad.2007.01.006

Suppes T, 2007, Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists, Psychopharmacol Bull, 40, 22

10.1016/j.jad.2007.04.006

10.1097/chi.0b013e318040b25f

10.1080/00048670701689428

10.1007/BF02850000

10.1111/j.1399-5618.2007.00426.x

10.1111/j.1399-5618.2007.00520.x

10.1016/j.eurpsy.2007.07.005

Jakovljevic M, 2007, Mental disorders and metabolic syndrome: a fatamorgana or warning reality?, Psychiatr Danub, 19, 76

10.1345/aph.1K141

10.1159/000092219

10.1176/ajp.2006.163.10.1821

10.1097/JCP.0b013e318166c4d5

10.1038/sj.jid.5701033

10.1097/01.yic.0000224789.21406.81

Food and Drug Administration.Information for Healthcare Professionals: Carbamazepine. Available at:http://www.fda.gov/cder/drug/InfoSheets/HCP/carbamazepineHCP.htm. Accessed January 24 2009.